Results 171 to 180 of about 10,600 (216)
Some of the next articles are maybe not open access.
Safety of Recombinant Zoster Vaccine in Rheumatology Patients
Southern Medical Journal, 2022Recombinant zoster vaccine (RZV) is Food and Drug Administration approved for the prevention of herpes zoster (shingles) in adults 50 years old and older. Immunocompromised subjects were excluded from the pivotal vaccine trials. We studied the safety of this vaccine in our university-affiliated rheumatology practice.This was a single-center ...
Syed, Raza +3 more
openaire +2 more sources
Presumed Herpes Zoster Ophthalmicus Reactivation Following Recombinant Zoster Vaccination
Cornea, 2020Purpose: To report a case of herpes zoster ophthalmicus (HZO) reactivation after recombinant zoster vaccination. Methods: A 78-year-old woman, with a history of HZO 20 years ago, was referred for progressive corneal thinning in her left eye that started 1 week after her second dose ...
Samir, Jabbour +3 more
openaire +2 more sources
Recombinant Zoster Vaccine (Shingrix) to Prevent Herpes Zoster
Nursing for Women's Health, 2018Women ages 50 years and older are at risk for herpes zoster, a reactivated virus from varicella zoster virus (chickenpox) that causes a painful vesicular rash and can result in postherpetic neuralgia. It is estimated that one in three adults will be affected by herpes zoster in their lifetime.
Jacqueline R. Sly, Allyssa L. Harris
openaire +2 more sources
Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine
Annals of Pharmacotherapy, 2018Objectives: To review the immunogenicity, efficacy, and safety of the herpes zoster subunit vaccine (HZ/su) for use in adult patients for the prevention of shingles. Data Sources: A literature search through PubMed was conducted (June 2008 to October 2017) using the terms shingles vaccine and varicella zoster virus.
James, Stephanie +3 more
openaire +2 more sources
Insurance reimbursements for recombinant zoster vaccine in the private sector
Vaccine, 2021A two-dose series of the recombinant zoster vaccine (RZV, Shingrix) was licensed by the Food and Drug Administration in 2017 and recommended by the Advisory Committee on Immunization Practices in 2018 for adults in the United States age 50 years and older.
Andrew J. Leidner +4 more
openaire +2 more sources
Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster
Drugs & Aging, 2018Shingrix® is a recombinant zoster vaccine (RZV) that contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system. The subunit vaccine is approved for the prevention of herpes zoster (HZ) [EU, USA, Japan, Canada and Australia] and postherpetic neuralgia (PHN) [EU and Australia] in adults aged ≥ 50 years.
openaire +2 more sources
Risk of Herpes Zoster Ophthalmicus Recurrence After Recombinant Zoster Vaccination
JAMA OphthalmologyImportanceThe recombinant zoster vaccine (RZV) is currently recommended for immunocompetent adults aged 50 years or older and immunocompromised adults aged 19 years or older and is effective in preventing herpes zoster ophthalmicus (HZO). However, questions about the safety of RZV in patients with a history of HZO remain.ObjectiveTo evaluate whether ...
Anushka, Walia +2 more
openaire +2 more sources
Impact of a pharmacist-driven recombinant zoster vaccine administration program
Journal of the American Pharmacists Association, 2021To determine whether a pharmacist-driven recombinant zoster vaccine (RZV) administration pilot program within a human immunodeficiency virus/infectious diseases clinic setting increased the completion of the 2-dose series when compared with standard care.In this retrospective cohort study, the patients enrolled in a pharmacist-driven RZV administration
Allison M. Porter, Patricia Pecora Fulco
openaire +2 more sources